Framework for Biomarker Discovery Using Plasma Proteomics Developed by CDER Researchers
Researchers at the FDA's Center for Drug Evaluation and Research (CDER) have developed a structured and systematic framework for biomarker discovery using plasma proteomics. Biomarkers are characteristics that can be measured and evaluated as indicators of biological processes or responses to therapeutic interventions. They are essential tools in drug development and regulatory evaluation. Traditional biomarker discovery methods often rely on hypothesis-driven approaches targeting a single molecule, which can miss broader patterns of drug response or fail to capture the full spectrum of molecular changes accompanying disease progression or therapeutic intervention. These limitations are particularly evident in complex or rare diseases, where multiple biological pathways interact, and limited sample sizes constrain statistical power.
To evaluate the utility of omics technologies for biomarker discovery in drug development and regulatory evaluation, CDER scientists have assessed aptamer-based plasma proteomics as a representative high-throughput omics approach. This work addresses the challenge of integrating novel, data-rich biomarker strategies into drug development. The plasma proteomics framework developed by CDER researchers demonstrates how proteomics methods and analytical frameworks can be designed, executed, and interpreted with scientific rigor, reproducibility, and regulatory relevance, establishing a foundation for biomarker discovery applicable across various therapeutic areas.
The large-scale method uses DNA sequences that bind specifically to proteins to measure thousands of proteins in plasma samples simultaneously. This method allows researchers to capture a comprehensive analysis of how drugs affect multiple biological pathways, revealing pharmacodynamic responses and mechanistic insights that extend beyond traditional single-target approaches. This work reflects an emerging direction in regulatory science, applying large-scale omics analysis to understand biological responses to therapeutic products in a structured, data-driven manner.
For biomarkers to be useful in drug regulation, they must be accurate, clearly show how the drug affects the body, and produce reliable results when tested repeatedly. Plasma proteomics offers a path forward for discovering comprehensive biomarkers that meet these criteria, but it introduces its own considerations. High-dimensional protein data require sophisticated analytical methods to extract meaningful biological insights, and variability between samples must be tightly controlled. Like other biomarker discovery methods, plasma proteomics faces challenges when sample numbers are extremely small, such as in single-patient scenarios in ultra-rare diseases, highlighting the importance of robust analytical frameworks for reliable biomarker identification.
To address these challenges, CDER researchers developed a systematic framework for biomarker discovery using plasma proteomics. This framework was established through complementary studies, demonstrating the Discovery phase and reproducing findings in the Replication phase, further evaluating biomarkers in the Characterization phase.
Together, these steps define a pathway for converting high-dimensional proteomic data into interpretable, mechanistically grounded evidence for drug development and regulatory evaluation across therapeutic areas. This approach utilized existing omics knowledge from other scientific fields, including study design principles and best practices, ensuring proper technology use and generating reliable, meaningful results. The framework was designed to include three phases: Discovery, Replication, and Characterization, based on available FDA recommendations for this specific biomarker type. Researchers addressed several key factors throughout the process, including controlling differences during sample collection and processing and ensuring consistent results when experiments are repeated. This framework is broadly applicable across therapeutic areas and different types of biomarkers, including pharmacodynamic, toxicity, and surrogate markers. By combining Discovery, Replication, and Characterization in a single framework, this approach creates a standardized and reproducible pathway for proteomic-based biomarker assessment. This methodology may be particularly valuable in rare diseases and emerging therapeutic areas, where patient numbers are small, enabling systematic identification and confirmation of mechanistically relevant biomarkers. By defining best practices for analytical quality and tracking changes over time, this framework provides an approach for biomarker discovery that aligns with FDA principles of transparency, reproducibility, and data integrity.
Applying this systematic plasma proteomic biomarker framework can accelerate drug development by providing early, mechanistic insights into therapeutic effects and enabling informed decision-making in clinical trials through the selection of robust, biologically relevant biomarkers. Such biomarkers can guide dose selection, inform patient selection, serve as endpoints to measure treatment response, support monitoring of safety or toxicity, and allow smaller, more efficient studies, especially in rare or complex diseases. While plasma proteomics offers broad insight into drug response, it also introduces technical and analytical complexities. Careful control of preanalytical variation, assay sensitivity, data variability, and statistical and computational analysis is essential to ensure reliable, reproducible, and interpretable biomarker data suitable for regulatory use. The challenge lies not only in managing the technology but also in defining each biomarker's context of use to build confidence in its interpretation. Insights gained from this work offer a regulatory science roadmap for integrating innovative analytical strategies into broader drug evaluation. By connecting molecular-scale discoveries to clinical and regulatory decision-making, this approach helps ensure that emerging omics technologies are applied responsibly and effectively.




